Advertisement

Search Results for "biosimilars"

Forbes List Logo
Biocon's high-risk, high-rewards biosimilars strategy unpacked
Founder-chairperson Kiran Mazumdar-Shaw believes the company's biggest acquisition will be a game changer for Biocon over the next decade
ByHarichandan Arakali
Biocon strikes partnership with Sandoz to tap biosimilars opportunity
ByHarichandan Arakali
US FDA approval puts India on the global map of biosimilars: Kiran Mazumdar-Shaw
ByHarichandan Arakali
Duncan Emerton at Pharma Intelligence on the biosimilars opportunity propelling Biocon's $3.3 bln Viatris deal
ByHarichandan Arakali
Biocon buys Viatris biosimilars unit for $3.34 bln; Infosys launches 'Metaverse Foundry'; Prime closes Fund IV at $120 mln
ByHarichandan Arakali

Latest News

Photo of the day: India Art Fair kicks off in Delhi
ByForbes India
RBI likely to hold interest rates in February 6 policy meet
BySalil Panchal
Economists flag upside to India growth after US tariff deal, but hold forecasts
BySamreen Wani
Why current tech stacks will fail DPDP (And what needs to change)
ByRoshmik Saha
Non-veg milk: The bone of contention in India-US trade deal
BySamidha Jain
Graphic of the day: Tariff relief cost: $2.5 trillion
BySamreen Wani
Why India’s IT giants are worried about Anthropic’s Claude Cowork
ByNaini Thaker
India’s concert economy: Booming sales, lagging infrastructure
ByNaini Thaker,Himani Kothari
AI agents form their own social network, humans left fascinated and alarmed
ByNaini Thaker
Advertisement
Advertisement

On Everyone’s Radar

Advertisement